{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:40:37Z","timestamp":1792507237955,"version":"4.5.0"},"reference-count":19,"publisher":"Media Sphere Publishing House","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2026,10,20]]},"abstract":"<jats:p>Objective. To evaluate the efficacy of sequential Mexidol therapy, administered intravenously and orally over 74 days as part of a comprehensive treatment regimen, on cognitive status in elderly patients with chronic cerebral ischemia (CCI) and cognitive impairments. Material and methods. AThis prospective open-label study included 90 elderly patients with CCI (mean age 81\u00b13 years). The main group (MG, n=43) received standard therapy plus Mexidol, and the comparison group (CG, n=47) received standard therapy alone. Cognitive function was assessed using the Mini-Mental State Examination (MMSE), Stroop test, and Schulte test at baseline and after three months. Results. At baseline, the groups were comparable in sex, age, and clinical and cognitive status. After three months of therapy, the median MMSE score in the main group (MG) was 27 points, significantly higher than the 26 points observed in the comparison group (CG) (p&lt;0.001; \u0394=8.0%). In the MG, no patients had mild dementia, whereas the percentage in the CG remained unchanged at 18.6%. In the Stroop test, the increase in the number of words named in the MG was 7 (95% CI 5; 8), compared to 2 (95% CI 0; 3) in the CG; the median was 70 and 66 words, respectively (\u0394=8.0%; p&lt;0.001). Nine patients (21.9%) in the CG scored fewer than 65 words, while none in the MG did so. The interference ratio decreased by 5.5% in the MG compared to 2.5% in the CG (p=0.004). The time to complete the Schulte test in the MG decreased by 8.0 seconds (95% CI \u201310.9; \u20135.1), compared to 2.0 seconds (95% CI \u20134.8; 0.8) in the CG; the difference between groups was 6.0 seconds (95% CI \u20139.2; \u20132.8). Work efficiency (WE) increased from 0.14 to 0.19 in the MG (35.7%), and by 6.7% in the CG. Four patients in the MG (9.3%) and nine in the CG (19.1%) had WE &gt;0.25. Mental stability improved by \u20134.0% (95% CI \u20136.3%; \u20131.7%) in the MG versus \u20131.0% (95% CI \u20133.2%; +1.2%) in the CG, with a difference of 3.0% (95% CI \u20136.2%; +0.2%; p&gt;0.05). Conclusions. Sequential administration of Mexidol as part of comprehensive therapy in elderly patients with chronic cerebral ischemia led to greater improvements in cognitive status, speed and efficiency of mental performance, cognitive control, and mental resilience than standard therapy alone. These findings indicate pro-cognitive and neuroprotective effects of Mexidol.<\/jats:p>","DOI":"10.17116\/jnevro202612609184","type":"journal-article","created":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:48:20Z","timestamp":1792504100000},"page":"84","source":"Crossref","is-referenced-by-count":0,"title":["Cognitive status in elderly patients with chronic cerebral ischemia treated with Mexidol"],"prefix":"10.17116","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-6529","authenticated-orcid":false,"given":"O.A.","family":"Osipova","sequence":"first","affiliation":[{"name":"Belgorod State National Research University","place":["Belgorod, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8771-2558","authenticated-orcid":false,"given":"E.V.","family":"Gosteva","sequence":"additional","affiliation":[{"name":"Belgorod State National Research University","place":["Belgorod, Russia"]},{"name":"Voronezh State Medical University named after N.N. Burdenko","place":["Voronezh, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-519X","authenticated-orcid":false,"given":"U.S.","family":"Moskvitina","sequence":"additional","affiliation":[{"name":"Belgorod State National Research University","place":["Belgorod, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202612609184-1","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro2025125337"},{"key":"key-10.17116\/jnevro202612609184-2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08984"},{"key":"key-10.17116\/jnevro202612609184-3","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/261702"},{"key":"key-10.17116\/jnevro202612609184-4","doi-asserted-by":"publisher","DOI":"10.1037\/pag0000288"},{"key":"key-10.17116\/jnevro202612609184-5","doi-asserted-by":"publisher","DOI":"10.1037\/pag0000070"},{"key":"key-10.17116\/jnevro202612609184-6","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15341"},{"key":"key-10.17116\/jnevro202612609184-7","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro201911909139"},{"key":"key-10.17116\/jnevro202612609184-8","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro2025125111132"},{"key":"key-10.17116\/jnevro202612609184-9","unstructured":"Torshin IJ, Gromova OA, Sardaryan IS, et al. Comparative chemoreactome analysis of mexidol. Pharmacokinetics and Pharmacodynamics. 2016;(4):19-30. (In Russ.)"},{"key":"key-10.17116\/jnevro202612609184-10","doi-asserted-by":"publisher","DOI":"10.37482\/2687-1491-Z184"},{"key":"key-10.17116\/jnevro202612609184-11","unstructured":"Rubinshtejn SYa. Ehksperimental\u2019nye metodiki patopsihologii. M.: ZAO Izd-vo EHKSMO-Press, 1999. 448 s"},{"key":"key-10.17116\/jnevro202612609184-12","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro20151152171-74"},{"key":"key-10.17116\/jnevro202612609184-13","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro2020120061119"},{"key":"key-10.17116\/jnevro202612609184-14","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202412401182"},{"key":"key-10.17116\/jnevro202612609184-15","unstructured":"Abramenko YuV. The assessment of the clinical efficacy, vasoactive and metabolic effects of mexidol in elderly patients with discirculatory encephalopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(11):35-41. (In Russ.)"},{"key":"key-10.17116\/jnevro202612609184-16","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202312304178"},{"key":"key-10.17116\/jnevro202612609184-17","doi-asserted-by":"publisher","DOI":"10.33667\/2078-5631-2023-21-7-12"},{"key":"key-10.17116\/jnevro202612609184-18","doi-asserted-by":"crossref","unstructured":"Ostroumova OD, Plotnikova NA, Kochetkov AI, et al. Ethylmethylhydroxypyridine succinate and evidence-based neuroprotection: trends and perspectives. Medical Alphabet. 2025;(36):7-13. (In Russ.)","DOI":"10.33667\/2078-5631-2025-36-7-13"},{"key":"key-10.17116\/jnevro202612609184-19","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202512505122"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:48:54Z","timestamp":1792504134000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2026\/9\/1199772982026091084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,10,20]]}},"alternative-id":["10.17116\/jnevro202612609184"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202612609184","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,20]]}}}